Kristie L. Kahl: What are the current treatment options for VHL-mutated tumors? Stacy Lloyd: While we currently know a lot more, probably more than ever before about VHL, there are still no FDA ...

The von Hippel–Lindau (vHL) phenotype is variable, which complicates genetic counseling and surveillance. We describe how the rate of new tumor development varies through the lifetimes of vHL patients ...

CURE spoke with Stacy Lloyd, board member of the VHL Alliance, about disparities seen in VHL and its patient population. Stacy Lloyd: There is a lack of awareness and knowledge about the disease in ...

The approval was based on data from an open-label phase 2 study which evaluated the efficacy and safety of Welireg in patients with von Hippel-Lindau-associated renal cell carcinoma and other ...

In Patients With Renal Cell Carcinoma Receiving Everolimus, Acute Kidney Injury is Common Belzutifan is a potent and selective inhibitor of HIF-2α. The Food and Drug Administration (FDA) has granted ...

Von-Hippel-Lindau (VHL) syndrome is an autosomal dominant disease caused by a germline mutation in VHL tumor suppressor gene. The disease, which was first described by Eugen von Hippel and Arvid ...

Merck & Co’s – known as MSD outside of the US and Canada – Welireg (belzutifan) has been conditionally approved by the European Commission (EC) as a monotherapy for certain patients with von ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time results from a Phase 2 trial evaluating the hypoxia-inducible factor ...

DALLAS--(BUSINESS WIRE)--Peloton Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing first-in-class oral medicines for cancer and other serious conditions, announced the ...

Von Hippel-Lindau (VHL) syndrome is a rare genetic disorder inherited in an autosomal dominant manner. The disease is characterized by hemangioblastomas or slow-growing vascular tumors of the brain, ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved belzutifan for treatment of cancers associated with von Hippel-Lindau disease. The indication ...